civorebrutinib   Click here for help

GtoPdb Ligand ID: 12868

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The structure for civorebrutinib was obtained from proposed INN list 129 (August 2023), where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is claimed in patent WO2019091440A1 (SINOMAB Bioscience) [1]. Review of SINOMAB's online pipeline page suggests that civorebrutinib is likely their lead BTK inhibitor SN1011.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 133.33
Molecular weight 463.92
XLogP 2.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=C(C=CC(=C1)OC2=CC=C(C=N2)Cl)C3=NN([C@@H]4CCC5(CC5)N(C4)C#N)C(=C3C(=O)N)N
Isomeric SMILES NC1=C(C(=NN1[C@H]2CN(C3(CC3)CC2)C#N)C4=CC=C(C=C4)OC5=NC=C(C=C5)Cl)C(=O)N
InChI InChI=1S/C23H22ClN7O2/c24-15-3-6-18(28-11-15)33-17-4-1-14(2-5-17)20-19(22(27)32)21(26)31(29-20)16-7-8-23(9-10-23)30(12-16)13-25/h1-6,11,16H,7-10,12,26H2,(H2,27,32)/t16-/m1/s1
InChI Key OSEITUBGGJDFBK-MRXNPFEDSA-N
Bioactivity Comments
In a small kinase screen, civorebrutinib was selective for BTK compared to LCK, SRC, LYN, ITK, TEC and EGFR [1]. In comparison ibrutinib was equipotent at all of these enzymes. Civorebrutinib inhibits B cell activation in vitro with an IC50 <10 nM.